Diagnostic or Therapeutic Strategies for Pregnancy Complications

It is well known that pregnancy complications, including preeclampsia, preterm birth, stillbirth, and intrauterine growth restriction affect over 12% of all pregnancies worldwide. These complications negatively impact both maternal and neonatal health and have short- and long-term effects such as an...

Full description

Saved in:
Bibliographic Details
Other Authors: Heazell, Alexander (Editor), Girard, Sylvie (Editor)
Format: Electronic Book Chapter
Language:English
Published: Basel MDPI - Multidisciplinary Digital Publishing Institute 2022
Subjects:
Online Access:DOAB: download the publication
DOAB: description of the publication
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000naaaa2200000uu 4500
001 doab_20_500_12854_97429
005 20230220
003 oapen
006 m o d
007 cr|mn|---annan
008 20230220s2022 xx |||||o ||| 0|eng d
020 |a books978-3-0365-4878-4 
020 |a 9783036548777 
020 |a 9783036548784 
040 |a oapen  |c oapen 
024 7 |a 10.3390/books978-3-0365-4878-4  |c doi 
041 0 |a eng 
042 |a dc 
072 7 |a M  |2 bicssc 
100 1 |a Heazell, Alexander  |4 edt 
700 1 |a Girard, Sylvie  |4 edt 
700 1 |a Heazell, Alexander  |4 oth 
700 1 |a Girard, Sylvie  |4 oth 
245 1 0 |a Diagnostic or Therapeutic Strategies for Pregnancy Complications 
260 |a Basel  |b MDPI - Multidisciplinary Digital Publishing Institute  |c 2022 
300 |a 1 electronic resource (238 p.) 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
506 0 |a Open Access  |2 star  |f Unrestricted online access 
520 |a It is well known that pregnancy complications, including preeclampsia, preterm birth, stillbirth, and intrauterine growth restriction affect over 12% of all pregnancies worldwide. These complications negatively impact both maternal and neonatal health and have short- and long-term effects such as an increased risk of neurodevelopmental and cardiovascular diseases. Over the past decade, numerous groups have investigated the use of new and/or existing drugs to either prolong gestation, such as in cases of threatened preterm labour; alleviate hypertension in preeclampsia; or promote adequate blood flow and nutrient delivery to the placenta to facilitate growth in IUGR. The overarching goal has been to promote healthier pregnancies and neonatal health, but it has been difficult to translate this work into the clinical setting, with problems in terms of drug delivery, specificity, and importantly, the early diagnostic capacities for complications in pregnancy. This book focuses on the early detection, potential novel therapeutic targets, risk factors, maternal outcomes, and long-term consequences of this critical problem. 
540 |a Creative Commons  |f https://creativecommons.org/licenses/by/4.0/  |2 cc  |4 https://creativecommons.org/licenses/by/4.0/ 
546 |a English 
650 7 |a Medicine  |2 bicssc 
653 |a ultrasonography 
653 |a elastography 
653 |a uterine cervix 
653 |a term pregnancy 
653 |a parturition 
653 |a genotyping 
653 |a preeclampsia 
653 |a MMP-9 
653 |a MMP-2 
653 |a SNPs 
653 |a tocolytic 
653 |a preterm birth 
653 |a preterm labor 
653 |a neonate 
653 |a prematurity 
653 |a pregnancy 
653 |a therapeutic 
653 |a progesterone 
653 |a fetus 
653 |a sex as a biological variable 
653 |a sex differences 
653 |a pregnancy complications 
653 |a placenta 
653 |a prenatal diagnosis 
653 |a fetal growth restriction 
653 |a miscarriage 
653 |a chorio-deciduitis 
653 |a grade 
653 |a amnionitis 
653 |a acute histologic chorioamnionitis 
653 |a intra-amniotic inflammatory response 
653 |a beta-blocker 
653 |a endothelial dysfunction 
653 |a cardiovascular disease 
653 |a pregnancy loss 
653 |a immunology 
653 |a vascular endothelial growth factor 
653 |a galectin-9 
653 |a interleukin-4 
653 |a proteomics 
653 |a urine 
653 |a biomarkers 
653 |a IBP4 
653 |a SHBG 
653 |a RPL 
653 |a NK cells 
653 |a sildenafil 
653 |a PDE5A 
653 |a VEGF-A 
653 |a angiotensin 
653 |a infant 
653 |a newborn 
653 |a female 
653 |a abruptio placentae 
653 |a Apgar score 
653 |a pregnant women 
653 |a gestational age 
653 |a IL-1 blockade 
653 |a anakinra 
653 |a canakinumab 
653 |a human 
653 |a inflammation 
653 |a fetal growth restriction (FGR) 
653 |a intra-uterine growth restriction (IUGR) 
653 |a SPINT1 
653 |a HAI-1 
653 |a stillbirth 
653 |a placental insufficiency 
653 |a histopathology 
653 |a cardiovascular risk 
653 |a postpartum screening 
653 |a n/a 
856 4 0 |a www.oapen.org  |u https://mdpi.com/books/pdfview/book/5950  |7 0  |z DOAB: download the publication 
856 4 0 |a www.oapen.org  |u https://directory.doabooks.org/handle/20.500.12854/97429  |7 0  |z DOAB: description of the publication